Hierarchy of Impairment of Spinal Mobility Measures in Ankylosing Spondylitis: Twelve-Year Data

Size: px
Start display at page:

Download "Hierarchy of Impairment of Spinal Mobility Measures in Ankylosing Spondylitis: Twelve-Year Data"

Transcription

1 Arthritis Care & Research Vol. 67, No. 11, November 2015, pp DOI /acr VC 2015, American College of Rheumatology ORIGINAL ARTICLE Hierarchy of Impairment of Spinal Mobility Measures in Ankylosing Spondylitis: Twelve-Year Data SOFIA RAMIRO, 1 ROBERT B. M. LANDEW E, 2 D ESIR EE VAN DER HEIJDE, 3 CARMEN STOLWIJK, 4 MAXIME DOUGADOS, 5 FILIP VAN DEN BOSCH, 6 AND ASTRID VAN TUBERGEN 4 Objective. To investigate which spinal mobility measures (SMMs) are most frequently impaired in patients with ankylosing spondylitis (AS), whether a hierarchy of impairment can be established, and whether assessing fewer measures sufficiently captures impairment in spinal mobility. Methods. Patients from the Outcome in Ankylosing Spondylitis International Study were followed up for 12 years. SMMs were considered impaired when falling below predefined cutoffs, derived from normal individuals. The proportion of patients in whom each SMM was impaired was calculated using baseline observation. In patients with 1 impaired SMM, we investigated how often impairment in spinal mobility would be missed if only a fixed number of SMMs was assessed. Analyses were repeated using all 12-year observations. Results. A total of 216 patients were included (70% males). Lateral spinal flexion (LSF) was the most frequently impaired measure, followed by the modified Schober (mschober) test, tragus-to-wall, cervical rotation, intermalleolar distance, and chest expansion measures, respectively. This hierarchy was strikingly consistent over time, and independent of sex, symptom duration, and presence of syndesmophytes. In patients with 1 impaired SMM, LSF was impaired most frequently (86%), followed by the mschober test (58%). If only LSF was measured, 14% of patients with impairment in any SMM would be missed; if additionally the mschober test was measured, 9% would be missed. Conclusion. LSF followed by the mschober test are the most frequently impaired mobility measures in AS, reflecting an earlier involvement of the lumbar spine, followed by involvement of the thoracic and cervical spine. In clinical practice LSF and the mschober test suffice to screen impairment in spinal mobility. INTRODUCTION Impairment of spinal mobility is widely recognized as an important clinical sign and a hallmark of axial spondyloarthritis (SpA). This is reflected by its inclusion in the modified New York Criteria for the classification of ankylosing spondylitis (AS) and in the core set of domains for the evaluation of patients with SpA in clinical practice Dr. Ramiro s work was supported by the Fundaç~ao para a Ci^encia e Tecnologia (grant SFRH/BD/68684/20). 1 Sofia Ramiro, MD, MSc: Amsterdam Rheumatology Center, University of Amsterdam, Amsterdam, The Netherlands, and Hospital Garcia de Orta, Almada, Portugal; 2 Robert B. M. Landewe, MD, PhD: Amsterdam Rheumatology Center, University of Amsterdam, Amsterdam, and Atrium Medical Center, Heerlen, The Netherlands; 3 Desiree van der Heijde, MD, PhD: Leiden University Medical Center, Leiden, The Netherlands; 4 Carmen Stolwijk, MD, Astrid van Tubergen, MD, PhD: Maastricht University Medical Center and University of Maastricht, Maastricht, The Netherlands; 5 Maxime Dougados, MD: Paris Descartes University, Cochin Hospital, AP-HP, INSERM (U1153), PRES, Sorbonne Paris-Cite, France; 6 Filip van den Bosch, MD, PhD: Ghent University Hospital and Ghent University, Ghent, Belgium. and trials, as defined by the Assessment of Spondylo- Arthritis international Society (ASAS) (1). A study on the natural course of AS conducted in the pre biologic agent era described that in the long term more than half of all patients will develop moderate to severe impairment of spinal mobility (2). Spinal mobility is one of the central outcomes included in observational and treatment studies in axial SpA (3,4) and is a predictor of poor prognosis (3). The spinal mobility measures (SMMs) recommended by ASAS are chest expansion, modified Schober test (mschober; 10 cm), occiput-to-wall distance (OTW), cervical rotation, and either lateral spinal flexion (LSF) or Bath Ankylosing Spondylitis Metrology Index (BASMI) (5,6). The Dr. van den Bosch has received speaking fees, consulting fees, and/or honoraria (less than $10,000 each) from AbbVie, Celgene, Pfizer, Novartis, and UCB. Address correspondence to Sofia Ramiro, MD, MSc, Department of Clinical Immunology and Rheumatology, Amsterdam Rheumatology Center, University of Amsterdam, Meibergdreef 9, Amsterdam 1105 AZ, The Netherlands. sofiaramiro@ gmail.com. Submitted for publication October 7, 2014; accepted in revised form May 5,

2 1572 Ramiro et al Significance & Innovations In ankylosing spondylitis, impaired spinal mobility occurs first in the lumbar spine, followed by the thoracic and cervical spine. This order of occurrence persists independently of sex, symptom duration, or presence of baseline syndesmophytes. In clinical practice, the measurement of lateral spinal flexion and the modified Schober test suffice to screen for impairment in spinal mobility. If lateral spinal flexion and modified Schober test are impaired, additional spinal mobility measures are necessary to assess the total level of spinal involvement. BASMI, in turn, includes LSF, the mschober test, cervical rotation, tragus-to-wall distance (TTW), and intermalleolar distance (IMD) (5). LSF and BASMI have shown the best discrimination between patients with and without structural damage (7). A normal LSF finding is the best predictor of the absence of radiographic damage, while an abnormal mschober test finding best predicts its presence. Furthermore, LSF and cervical rotation more consistently discriminated between active treatment and placebo, and between responders and nonresponders in randomized controlled trials with tumor necrosis factor (TNF) inhibitors (8,9). However, to our knowledge it has never been investigated whether specific SMMs are more frequently impaired than others in patients with AS compared to normal individuals, and whether there is a certain sequential or hierarchical order in the occurrence of impairment. Such an analysis was hampered by the lack of normal values for SMMs. We have recently described reference intervals and percentile curves for SMMs obtained in normal individuals (10). In the present study, we have used these percentile curves for SMMs to perform a formal age-matched comparison with values obtained from patients with AS. The aim of this study was to investigate which SMMs are most frequently impaired in patients with AS, whether a hierarchical order in the occurrence of impairment could be established, and whether this would be dependent on characteristics such as symptom duration. Furthermore, we have investigated whether assessing fewer measures could still capture sufficient information for detecting impairment of spinal mobility. approved the study. All patients have provided written informed consent. Spinal mobility measures. Six SMMs were analyzed in this study: chest expansion, mschober test, cervical rotation, LSF, TTW, and IMD. Measurements were performed according to the ASAS recommendations, and the reference values were obtained using these same assessments (6,10). The better of 2 tries for each measurement was recorded. All measurements were recorded in centimeters, except for cervical rotation, which was recorded in degrees. All measurements were rounded to decimals, except for IMD and cervical rotation, which were rounded to units. Additionally, the BASMI (5) (range 0 10, with a higher score representing a worse mobility) was computed according to the BASMI linear formula (12). In the first 2 years, LSF has erroneously been recorded as the distance from middle fingertip to floor on maximum flexion for Dutch patients. This means that the fingertip to MATERIALS AND METHODS Study population. For this study, data from the Outcome in Ankylosing Spondylitis International Study (OASIS) were used. OASIS is a prevalence cohort that started in 1996 and included 217 consecutive patients with AS from the Netherlands, Belgium, and France (11). Clinical data, including spinal mobility, were collected regularly during 12 years. In the first 2 years, spinal mobility was measured every 6 months and afterward every 2 years. All patients were included in the present study. The ethics committees of all participating hospitals have Figure 1. Lateral spinal flexion in function of age and with the percentile curves and help lines derived from measurements in normal individuals (10). Solid lines represent the percentile curves derived from normal individuals (percentiles indicated). Broken lines (a 0 to d 0 ) are help lines parallel to the percentile curves, derived to accommodate impaired values of patients with ankylosing spondylitis. Dots represent the real measurements of lateral spinal flexion of patients with ankylosing spondylitis at baseline (A) orinall12-yearobservations(b).

3 Impairment of Spinal Mobility in AS 1573 floor distance in a neutral position was missing, which hampers the calculation of the LSF. To replace this missing value and enable the computation of the LSF, we derived the neutral fingertip to floor distance from height according to an equation proposed for this purpose (13). Impairment in spinal mobility. Percentile curves (2.5th to 97.5th percentiles) were obtained for each of the SMMs from our previous study in normal individuals, the MOBIL- ITY study (10). Figure 1 illustrates such percentile curves for LSF as an example. These curves represent age-specific spinal mobility in normal individuals and its evolution by increasing age. The 2.5th and 97.5th percentile curves obtained in normal individuals correspond with Z scores of and (10). In patients with AS impaired mobility is expected in comparison with normal individuals. In order to better describe this level of impairment, we have introduced 4 additional parallel curves (help lines) to the mobility curves, corresponding with Z scores of (a 0 ); (b 0 ); (c 0 ); and (d 0 ), respectively (Figure 1). For every observation in OASIS, an SMM was defined as impaired if its value was below a certain cutoff (either the 2.5th percentile or one of the 4 help lines). OTW was not applied in this study, because percentile curves for this measure could not be derived. The reference value for OTW is zero and the vast majority of normal individuals indeed have an OTW of zero (10). We could have applied a value of zero here, but this value would be a static figure and would not change by increasing age or with the different percentile curves used, as opposed to what happens with the other measures. This would make the evaluation of the hierarchy for the impairment of the SMM across the different cutoffs complex or even impossible. We therefore used the TTW, which is another measure for cervical kyphosis. However, for TTW, no percentile curves had been derived in the MOBILITY study, with the rationale that this measure is strongly dependent on the conformation of the head and would therefore not be so relevant to derive reference intervals. For the purpose of the present study, percentile curves for TTW were derived following the methodology described for the MOBILITY study (for more details, see Supplementary Appendix A and Supplementary Figure 1, available in the online version of this article at com/doi/ /acr.22614/abstract) (10). Subgroup analysis. Impairment of spinal mobility was also investigated in subgroups of patients, taking into account variables that may influence spinal mobility. Subgroups were created based on sex, symptom duration (above and below the median [,18 years versus $18 years]), as well as in tertiles (,14 years, years, and $25.3 years), and the presence of baseline syndesmophytes (0 versus $1 and,5 versus $5). The scores on syndesmophytes from 2 readers (separate scores from each of the readers) were used (14). Subgroup analysis. We conducted 2 types of analyses. First, for each of the SMMs, the proportion of patients in which the SMM was impaired according to each of the cutoffs was calculated, using the baseline observation. For each of the cutoffs, measures were ranked according to the propor- Table 1. Impairment of each of the spinal mobility measures (SMMs) in patients with AS, defined according to age-specific cutoffs derived from normal subjects* 2.5th percentile, line a 0, line b 0, line c 0, line d 0, Total observations, no. Patient level (baseline only) Lateral spinal flexion (cm) 149 (73) 138 (68) 119 (59) 106 (52) 55 (27) 203 Modified Schober test (cm) 111 (55) 94 (46) 78 (38) 63 (31) 36 (18) 203 Tragus-to-wall distance (cm) 85 (42) 62 (31) 43 (21) 203 Cervical rotation (degrees) 55 (27)# 44 (22)# 38 (19)# 28 (14)# 26 (13)# 203 Intermalleolar distance (cm) 39 (19)** 27 (13) 22 (11) 12 (6) 8 (4) 203 Chest expansion (cm) 54 (27) 17 (8)** 4 (2)** 0 (0)** 0 (0)** 203 Observational level (all observations) Lateral spinal flexion (cm) 1,035 (73) 919 (65) 804 (57) 661 (46) 314 (22) 1,422 Modified Schober (cm) 845 (59) 696 (49) 571 (40) 453 (32) 282 (20) 1,422 Tragus-to-wall distance (cm) 622 (44) 490 (34) 342 (24) 1,422 Cervical rotation (degrees) 439 (31)# 349 (25)# 274 (19)# 215 (15)# 167 (12)# 1,422 Intermalleolar distance (cm) 320 (23)** 207 (15) 152 (11) 88 (6) 55 (4) 1,422 Chest expansion (cm) 386 (27) 139 (10)** 32 (2)** 4 (0)** 1 (0)** 1,422 * The first column refers to impairment defined as a value below the 2.5th percentile in normal individuals. The remaining columns refer to cutoffs defined on the basis of help lines, parallel to the percentile curves, derived to accommodate impaired values of patients with ankylosing spondylitis (AS; Figure 1). Impairment in spinal mobility is presented both at the patient level (using baseline observation) and observation level (all 12-year observations). SMM most frequently impaired. Second SMM most frequently impaired. Third SMM most frequently impaired. Not possible to derive these values due to mathematical characteristics of the equation for the percentile curves for tragus-to-wall distance. # Fourth SMM most frequently impaired. ** SMM least frequently impaired. Fifth SMM most frequently impaired.

4 1574 Ramiro et al tion of patients with impairment in each of the SMMs. Subsequently, we conducted a similar analysis, but now taking all observations over the 12 years per patient into account. Analyses were repeated in all the subgroups. The main analysis was conducted with patients (respectively, observations) in whom assessment of SMM was complete, i.e., all SMMs were assessed. Sensitivity analyses were conducted with patients (respectively, observations) in whom any SMM was available. For the second analysis, the number of patients with at least 1 impaired SMM was calculated, using the baseline observation. Each of the SMMs was defined as impaired if the value was below help line a 0 (first cutoff below normal individuals). Among the patients with at least 1 impaired SMM, the proportion of patients with each of the SMMs impaired was calculated. Furthermore, we investigated in how many cases impairment in spinal mobility (defined as impairment in at least 1 SMM) would be missed if only a fixed number of SMMs was assessed. Subsequently, we conducted the same analysis, but now taking all observations over the 12 years per patient into account. For this second analysis, only patients with complete assessments of SMMs were included. Analyses were done using Stata SE, version 12. RESULTS A total of 216 patients with the following baseline characteristics were included: 71% males, mean 6 SD age years, mean 6 SD symptom duration years, 85% HLA B27 positive, 68% treated with nonsteroidal antiinflammatory drugs, and none with biologic agents. Patients were on average followed up for years with a mean 6 SD of observations per patient with assessment of SMMs. At baseline, the mean 6 SD LSF was cm, mschober test was cm, TTW was cm, cervical rotation was degrees, IMD was cm, chest expansion was cm, and the BASMI was Hierarchy of impairment in spinal mobility. LSF was always the most frequently impaired measure, sequentially followed by the mschober test, TTW, cervical rotation, IMD, and chest expansion (Table 1). This order was strikingly similar for all cutoffs (with the only exception being the 2.5th percentile, for which chest expansion was slightly more frequently impaired than IMD). Using as a cutoff the help line a 0 (first cutoff below normal individuals), LSF was impaired in 68% of the patients, followed by the mschober test, which was impaired in 47% of the patients (Table 1). Impairment of BASMI, also defined according to help line a 0, occurred in 49% of the patients. The same hierarchy was found in the analyses including all 12-year observations (Table 1). Figure 1 (panel A at patient level, panel B at observation level) shows the percentile curves and help lines for LSF and the measured values for LSF (i.e., dots) below each cutoff. Table 2. Impairment of each of the spinal mobility measures (SMMs) in patients with AS, compared to cutoffs defined according to age-specific cutoffs derived from normal subjects and stratified for symptom duration (median)* 2.5th percentile, help line a 0, help line b 0, help line c 0, help line d 0, Total observations, no. Patients with shorter symptom duration (,18 years) Lateral spinal flexion (cm) 66 (69) 58 (60) 46 (48) 41 (43) 24 (25) 96 Modified Schober (cm) 47 (49) 41 (43) 30 (31) 25 (26) 15 (16) 96 Tragus-to-wall distance (cm) 29 (30) 21 (22) 14 (15) 96 Cervical rotation (degrees) 18 (19)# 14 (15)** 12 (13)** 10 (10)** 10 (10)** 96 Intermalleolar distance (cm) 15 (16) 9 (9)# 5 (5)# 3 (3)# 2 (2)# 96 Chest expansion (cm) 20 (21)** 4 (4) 0 (0) 0 (0) 0 (0) 96 Patients with longer symptom 96 duration ($18 years) Lateral spinal flexion (cm) 80 (83) 77 (80) 70 (73) 62 (65) 28 (29) 96 Modified Schober (cm) 60 (63) 50 (52) 45 (47) 35 (36) 18 (19) 96 Tragus-to-wall distance (cm) 51 (53) 38 (40) 27 (28) 96 Cervical rotation (degrees) 34 (35)** 28 (29)** 24 (25)** 17 (18)** 15 (16)** 96 Intermalleolar distance (cm) 21 (22) 17 (18)# 16 (17)# 8 (8)# 5 (5)# 96 Chest expansion (cm) 33 (34)# 13 (14) 4 (4) 0 (0) 0 (0) 96 * The first column refers to impairment defined as a value below the 2.5th percentile in normal individuals. The remaining columns refer to cutoffs defined on the basis of help lines, parallel to the percentile curves, derived to accommodate impaired values of patients with ankylosing spondylitis (AS; Figure 1). Impairment in spinal mobility is presented at the patient level (for observation level, all 12-year observations, see Supplementary Table 2, available in the online version of this article at SMM most frequently impaired. Second SMM most frequently impaired. Third SMM most frequently impaired. Not possible to derive these values due to mathematical characteristics of the equation for the percentile curves for tragus-to-wall distance. # Fifth SMM most frequently impaired. ** Fourth SMM least frequently impaired. SMM least frequently impaired.

5 Impairment of Spinal Mobility in AS 1575 Table 3. Impairment of each of the spinal mobility measures (SMMs) in patients/ observations with at least 1 impaired SMM* Patient level (baseline assessment), (n 5 161) Observation level, (n 5 1,111) Impairment in each of the SMMs Lateral spinal flexion 138 (86) 919 (83) Modified Schober test 94 (58) 696 (63) Tragus-to-wall distance 62 (39) 490 (44) Cervical rotation 44 (27) 349 (31) Intermalleolar distance 27 (17) 207 (19) Chest expansion 17 (11) 139 (13) Number of SMMs impaired 1 49 (30) 282 (25) 2 53 (33) 355 (32) 3 27 (17) 203 (18) 4 15 (9) 168 (15) 5 16 (10) 91 (8) 6 1 (1) 12 (1) Impairment in spinal mobility captured by fewer measures Lateral spinal flexion 138 (86) 919 (83) Lateral spinal flexion 1 modified Schober test 147 (91) 1,008 (91) Lateral spinal flexion 1 modified Schober test (96) 1,067 (96) tragus-to-wall distance Lateral spinal flexion 1 modified Schober test (99) 1,097 (99) tragus-to-wall distance 1 cervical rotation Lateral spinal flexion 1 modified Schober test 1 tragus-to-wall distance 1 cervical rotation 1 intermalleolar distance 160 (99) 1,108 (100) * Each of the SMMs was defined as impaired if the measurement fell below help line a 0 (first cutoff below normal individuals; see Figure 1). Among the patients (n 5 161) or observations (n 5 1,111) with at least 1 impaired SMM, the proportion of patients (respectively of observations) with each of the SMMs impaired was calculated. A sensitivity analysis, conducted with patients (respectively, observations) in whom any SMM was available, provided similar results (Supplementary Table 1, available in the online version of this article at wiley.com/doi/ /acr.22614/abstract). Also, after stratification for symptom duration (median), sex, or the presence of baseline syndesmophytes this hierarchy in general persisted, both at the patient level (Table 2 and Supplementary Tables 2 and 3) and at the observation level (example shown for symptom duration in Supplementary Table 4). Stratification for symptom duration in tertiles also retrieved the same results, as well as for the presence of baseline syndesmophytes according to the second reader (data not shown). Impairment in spinal mobility captured by fewer measures. Any impairment in spinal mobility was present in 161 of the 203 patients (79%) and in 1,111 of 1,422 observations (78%) with complete assessment of SMMs. Among patients with at least 1 impaired SMM, LSF was impaired in 86%, followed by the mschober test in 58%. One SMM was impaired in 30% of the patients, 2 SMMs were impaired in 33%, and 3 SMMs were impaired in 17% (Table 3). If only LSF was measured, 14% of the patients with impairment in SMMs would be missed since in these patients LSF was normal but another SMM was impaired. If the mschober test was measured in addition to LSF, only 9% of patients would be missed. When TTW was measured in addition to LSF and the mschober test, only 4% of the patients with impairment in mobility would be missed. Analyses taking into account all 12-year observations yielded similar results (Table 3). DISCUSSION In the present study we have shown that there is an order of involvement of the spine in AS; LSF and the mschober tests are the most frequently impaired mobility measures in AS, reflecting an earlier involvement of the lumbar spine in impairment in spinal mobility, followed by involvement of the thoracic and cervical spine. This order of involvement of the spine persists across different subgroups of patients based on sex, disease duration, or the presence of baseline syndesmophytes. To our knowledge the order of impairment in SMMs has never been investigated before. Therefore, we cannot compare our findings with others. Previous studies comparing spinal mobility in normal individuals and in patients with AS have focused on a single SMM and were performed in

6 1576 Ramiro et al the 1970s (15,16). Several factors, most importantly different measurement techniques, hamper a proper comparison with our results (15,16). The lack of studies comparing impairment in spinal mobility between patients with axial SpA and normal individuals can partly be explained by the fact that percentile curves from normal individuals did not exist until recently. With the age-adjusted percentile curves from the MOBILITY study (10), we now have better tools to compare spinal mobility between patients with axial SpA and normal individuals and across studies. Interestingly, the SMMs most frequently impaired, LSF and the mschober test, have also been identified as the ones best discriminating between patients with and without spinal radiographic damage (7). This reinforces their importance when assessing spinal mobility. Furthermore, LSF is considered the SMM that is most sensitive to change (8). The relationship between LSF (as a single measure) and radiographic damage has been shown to be as good as the relationship between BASMI (composite measure) and radiographic damage, and substantially better than the relationship between other SMMs and radiographic damage (7). Therefore, ASAS has recommended in the core set that the LSF can be used instead of the BASMI. Our findings endorse this idea, as we have found a higher proportion of observations with impaired LSF than with impaired BASMI, when comparing patients with normal individuals. Furthermore, LSF has been selected as one of the items of the ASAS 5/6 response criteria (17). From our study, it can be deduced that the detection of impairment of spinal mobility can be done by assessing only 2 SMMs: LSF and the mschober test. With this screening method, impairment of spinal mobility is only missed in 9% of the cases. We hereby recommend that these 2 measurements are minimally performed in order to determine impairment in spinal mobility in individual patients with AS. If these 2 are impaired, it is important to assess additional SMMs to be informed about the total level of spinal involvement. If LSF and the mschober test findings are normal, it is unlikely that other SMMs will be found abnormal. This is particularly useful for daily clinical practice, where it may sometimes be unfeasible, due to time constraints, to perform a complete BASMI or all SMMs, even though these are recommended by ASAS (1). We were unable to find any study investigating the feasibility of spinal mobility assessment in clinical practice, but it may well be the case that spinal mobility measurement is frequently skipped for time reasons. Of note, if impairment in LSF and/or the mschober test is identified, then a full assessment of all SMMs is still recommended, which will ultimately inform the rheumatologist about the severity of the disease and will likely guide clinical decisions, such as referral to physiotherapy and/or rehabilitation medicine. An important limitation of the study is that we have used a prevalence cohort of patients with AS and have neither taken into account the development of impairment of spinal mobility over time, or whether this also occurs in a fixed order. We have rather analyzed impairment in spinal mobility cross-sectionally at multiple time points. We have found a hierarchy in the occurrence of impairments per SMM and it is plausible that impairment in spinal mobility over time occurs in an order described in this study. Formally, this sequence needs to be prospectively validated, but that will be extremely difficult, since the results of our study indicate that for that purpose, an inception cohort is required in which patients virtually without impairments at baseline are followed for 30 or more years in order to prove the sequence we have proposed here in a longitudinal fashion. Moreover, a comparison was established between patients with AS and normal values derived from normal individuals. We can therefore not know whether these findings are specific for AS, or whether the same type of impairment would be found in other diseases affecting the spine, e.g., mechanical discopathy. Another possible critique is the imputation of LSF values of Dutch patients during the first 2 years. Even though the imputation method performed very well (13), we cannot fully exclude some possible errors. Strengths of our study are the formal comparison between patients with AS with percentile curves derived from normal individuals. We included a large number of measurements, and the hierarchy proposed persisted across subgroups, which adds credibility to the findings. Confirmation of our findings in another cohort, and also in earlier phases of the development of mobility impairment, e.g., in patients with nonradiographic axial SpA, are warranted. If confirmed, it would be interesting to explore what factors are associated with this higher impairment in mobility of the lumbar spine, compared to the cervical or thoracic spine. Inflammation may hypothetically be one of the factors involved, as we know that treatment with TNF inhibitors, which control inflammation and disease activity, is associated with improvement in spinal mobility (8,9). In summary, this study has shown that there is an order for impairment in spinal mobility and provides clinicians with a data-driven approach to screen impairment in spinal mobility by assessing the LSF and the mschober test in patients with AS. AUTHOR CONTRIBUTIONS All authors were involved in drafting the article or revising it critically for important intellectual content, and all authors approved the final version to be submitted for publication. Dr. Ramiro had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study conception and design. Ramiro, Landewe, van der Heijde, Dougados, van Tubergen. Acquisition of data. Ramiro, Landewe, Stolwijk, Dougados, van den Bosch. Analysis and interpretation of data. Ramiro, Landewe, van der Heijde, Dougados, van den Bosch, van Tubergen. REFERENCES 1. Van der Heijde D, Calin A, Dougados M, Khan MA, van der Linden S, Bellamy N. Selection of instruments in the core set for DC-ART, SMARD, physical therapy, and clinical record keeping in ankylosing spondylitis: progress report of the ASAS Working Group. Assessments in Ankylosing Spondylitis. J Rheumatol 1999;26:951 4.

7 Impairment of Spinal Mobility in AS Carette S, Graham D, Little H, Rubenstein J, Rosen P. The natural disease course of ankylosing spondylitis. Arthritis Rheum 1983;26: Amor B, Santos RS, Nahal R, Listrat V, Dougados M. Predictive factors for the long term outcome of spondyloarthropathies. J Rheumatol 1994;21: Laurent MR, Buchanan WW, Bellamy N. Methods of assessment used in ankylosing spondylitis clinical trials: a review. Br J Rheumatol 1991;30: Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A. Defining spinal mobility in ankylosing spondylitis (AS): the Bath AS Metrology Index. J Rheumatol 1994;21: Sieper J, Rudwaleit M, Baraliakos X, Brandt J, Braun J, Burgos-Vargas R, et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis 2009;68 Suppl 2: Wanders A, Landewe R, Dougados M, Mielants H, van der Linden S, van der Heijde D. Association between radiographic damage of the spine and spinal mobility for individual patients with ankylosing spondylitis: can assessment of spinal mobility be a proxy for radiographic evaluation? Ann Rheum Dis 2005;64: Van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebocontrolled trial (ASSERT). Arthritis Rheum 2005;52: Van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006;54: Ramiro S, van Tubergen A, Stolwijk C, van der Heijde D, Royston P, Landewe R. Reference intervals of spinal mobility measures in normal individuals: the MOBILITY study. Ann Rheum Dis 2015;74: Spoorenberg A, van der Heijde D, de Klerk E, Dougados M, de Vlam K, Mielants H, et al. Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. J Rheumatol 1999;26: Van der Heijde D, Landewe R, Feldtkeller E. Proposal of a linear definition of the Bath Ankylosing Spondylitis Metrology Index (BASMI) and comparison with the 2-step and 10- step definitions. Ann Rheum Dis 2008;67: Ramiro S, van Tubergen A, Stolwijk C, van der Heijde D, Landewe R. Neutral lateral fingertip-to-floor distance can be derived from height [letter]. Ann Rheum Dis 2014;73: Ramiro S, Stolwijk C, van Tubergen A, van der Heijde D, Dougados M, van den Bosch F, et al. Evolution of radiographic damage in ankylosing spondylitis: a 12 year prospective follow-up of the OASIS study. Ann Rheum Dis 2015;74: Moll JM, Wright V. An objective clinical study of chest expansion. Ann Rheum Dis 1972;31: Moll JM, Liyanage SP, Wright V. An objective clinical method to measure lateral spinal flexion. Rheumatol Phys Med 1972;11: Brandt J, Listing J, Sieper J, Rudwaleit M, van der Heijde D, Braun J. Development and preselection of criteria for short term improvement after anti-tnf a treatment in ankylosing spondylitis. Ann Rheum Dis 2004;63:

Ankylosing spondylitis: Assessment and analysis of long-term outcome Ramiro, S.

Ankylosing spondylitis: Assessment and analysis of long-term outcome Ramiro, S. UvA-DARE (Digital Academic Repository) Ankylosing spondylitis: Assessment and analysis of long-term outcome Ramiro, S. Link to publication Citation for published version (APA): Antunes da Cunha Oliveira

More information

5/4/2018. Outcome Measures in Spondyloarthritis. Learning Objectives. Outcome Measures Clinical Outcome Assessments

5/4/2018. Outcome Measures in Spondyloarthritis. Learning Objectives. Outcome Measures Clinical Outcome Assessments Outcome Measures in Spondyloarthritis Marina N Magrey MD Associate Professor Case Western Reserve University School of Medicine at MetroHealth Medical Center Learning Objectives What are outcome measures

More information

Performance of the Ankylosing Spondylitis Disease Activity Score (ASDAS) in patients under biological therapies

Performance of the Ankylosing Spondylitis Disease Activity Score (ASDAS) in patients under biological therapies Performance of the Ankylosing Spondylitis Disease Activity Score (ASDAS) in patients under biological therapies 1. Introduction The Ankylosing Spondylitis Disease Activity Score (ASDAS) is a new instrument

More information

Cover Page. The handle holds various files of this Leiden University dissertation

Cover Page. The handle   holds various files of this Leiden University dissertation Cover Page The handle http://hdl.handle.net/1887/43590 holds various files of this Leiden University dissertation Author: Machado, Pedro Title: Health and imaging outcomes in axial spondyloarthritis Issue

More information

Inter-rater reliability of clinical mobility measures in ankylosing spondylitis

Inter-rater reliability of clinical mobility measures in ankylosing spondylitis Calvo-Gutiérrez et al. BMC Musculoskeletal Disorders (2016) 17:382 DOI 10.1186/s12891-016-1242-1 RESEARCH ARTICLE Open Access Inter-rater reliability of clinical mobility measures in ankylosing spondylitis

More information

Do extra-articular manifestations influence outcome in ankylosing spondylitis? 12-year results from OASIS

Do extra-articular manifestations influence outcome in ankylosing spondylitis? 12-year results from OASIS Do extra-articular manifestations influence outcome in ankylosing spondylitis? 12-year results from OASIS I. Essers 1, S. Ramiro 2, C. Stolwijk 1, M. Blaauw 1, R. Landewé 3, D. van der Heijde 2, F. Van

More information

Clinical Tools to Assess and Monitor Spondyloarthritis

Clinical Tools to Assess and Monitor Spondyloarthritis Curr Rheumatol Rep (2015) 17: 47 DOI 10.1007/s11926-015-0522-3 SPONDYLOARTHRITIS (MA KHAN, SECTION EDITOR) Clinical Tools to Assess and Monitor Spondyloarthritis Robert Landewé 1,2 & Astrid van Tubergen

More information

Clinical and spinal radiographic outcome in axial spondyloarthritis Maas, Fiona

Clinical and spinal radiographic outcome in axial spondyloarthritis Maas, Fiona University of Groningen Clinical and spinal radiographic outcome in axial spondyloarthritis Maas, Fiona IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish

More information

Do HLA-B27 positive patients differ from HLA-B27 negative patients in clinical presentation

Do HLA-B27 positive patients differ from HLA-B27 negative patients in clinical presentation Do HLA-B27 positive patients differ from HLA-B27 negative patients in clinical presentation and imaging? Results from the DESIR cohort of patients with recent onset axial spondyloarthritis Ho Yin Chung

More information

Clinical and spinal radiographic outcome in axial spondyloarthritis Maas, Fiona

Clinical and spinal radiographic outcome in axial spondyloarthritis Maas, Fiona University of Groningen Clinical and spinal radiographic outcome in axial spondyloarthritis Maas, Fiona IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish

More information

Axial Spondyloarthritis. Doug White, Rheumatologist Waikato Hospital

Axial Spondyloarthritis. Doug White, Rheumatologist Waikato Hospital Axial Spondyloarthritis Doug White, Rheumatologist Waikato Hospital Disclosures Presentations / Consulting Abbott Laboratories AbbVie MSD Novartis Roche Clinical Trials Abbott Laboratories AbbVie Actelion

More information

Assessment of disability with the World Health Organisation Disability Assessment Schedule II in patients with ankylosing spondylitis

Assessment of disability with the World Health Organisation Disability Assessment Schedule II in patients with ankylosing spondylitis 140 EXTENDED REPORT Assessment of disability with the World Health Organisation Disability Assessment Schedule II in patients with ankylosing spondylitis A van Tubergen, R Landewé, L Heuft-Dorenbosch,

More information

SpA non-radiografica: fase precoce di spondilite anchilosante o altro?

SpA non-radiografica: fase precoce di spondilite anchilosante o altro? Rheumatology Department of Lucania, S. Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera SpA non-radiografica: fase precoce di spondilite anchilosante o altro? Ignazio Olivieri Disclosures

More information

Clinical and spinal radiographic outcome in axial spondyloarthritis Maas, Fiona

Clinical and spinal radiographic outcome in axial spondyloarthritis Maas, Fiona University of Groningen Clinical and spinal radiographic outcome in axial spondyloarthritis Maas, Fiona IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish

More information

A mong the inflammatory rheumatic diseases

A mong the inflammatory rheumatic diseases 659 REVIEW Early referral recommendations for ankylosing spondylitis (including pre-radiographic and radiographic forms) in primary care J Sieper, M Rudwaleit... An earlier diagnosis of ankylosing spondylitis

More information

Key words Ankylosing spondylitis, radiographic scoring methods, intra- and interobserver reliability, BASRI, msasss.

Key words Ankylosing spondylitis, radiographic scoring methods, intra- and interobserver reliability, BASRI, msasss. Radiological scoring methods for ankylosing spondylitis: a comparison between the Bath Ankylosing Spondylitis Radiology Index and the modified Stoke Ankylosing Spondylitis Spine Score F. Salaffi 1, M.

More information

BRIEF REPORT. Denis Poddubnyy, 1 Hildrun Haibel, 1 J urgen Braun, 2 Martin Rudwaleit, 3 and Joachim Sieper 1

BRIEF REPORT. Denis Poddubnyy, 1 Hildrun Haibel, 1 J urgen Braun, 2 Martin Rudwaleit, 3 and Joachim Sieper 1 ARTHRITIS & RHEUMATOLOGY Vol. 67, No. 9, September 2015, pp 2369 2375 DOI 10.1002/art.39225 VC 2015, American College of Rheumatology BRIEF REPORT Clinical Course Over Two Years in Patients With Early

More information

Assessment of fatigue in the management of patients with ankylosing spondylitis

Assessment of fatigue in the management of patients with ankylosing spondylitis Rheumatology Advance Access published September 16, 2003 Rheumatology 2003; 1 of 6 doi:10.1093/rheumatology/keg421, available online at www.rheumatology.oupjournals.org Assessment of fatigue in the management

More information

Nonsteroidal Antiinflammatory Drugs Reduce Radiographic Progression in Patients With Ankylosing Spondylitis

Nonsteroidal Antiinflammatory Drugs Reduce Radiographic Progression in Patients With Ankylosing Spondylitis ARTHRITIS & RHEUMATISM Vol. 52, No. 6, June 2005, pp 1756 1765 DOI 10.1002/art.21054 2005, American College of Rheumatology Nonsteroidal Antiinflammatory Drugs Reduce Radiographic Progression in Patients

More information

Are gender-specific approaches needed in diagnosing early axial spondyloarthritis? Data from the SPondyloArthritis Caught Early cohort

Are gender-specific approaches needed in diagnosing early axial spondyloarthritis? Data from the SPondyloArthritis Caught Early cohort Ortolan et al. Arthritis Research & Therapy (2018) 20:218 https://doi.org/10.1186/s13075-018-1705-x RESEARCH ARTICLE Are gender-specific approaches needed in diagnosing early axial spondyloarthritis? Data

More information

I n 1995, the ASsessment in Ankylosing Spondylitis

I n 1995, the ASsessment in Ankylosing Spondylitis 127 EXTENDED REPORT Assessment of enthesitis in ankylosing spondylitis L Heuft-Dorenbosch, A Spoorenberg, A van Tubergen, R Landewé, H van der Tempel, H Mielants, M Dougados, D van der Heijde... See end

More information

ARD Online First, published on October 11, 2005 as /ard

ARD Online First, published on October 11, 2005 as /ard ARD Online First, published on October 11, 2005 as 10.1136/ard.2005.044206 Combining information obtained from MRI and conventional radiographs in order to detect sacroiliitis in patients with recent-onset

More information

Ankylosing spondylitis functional and activity indices in clinical practice

Ankylosing spondylitis functional and activity indices in clinical practice Journal of Medicine and Life Vol. 7, Issue 1, JanuaryMarch 2014, pp.7883 Ankylosing spondylitis functional and activity indices in clinical practice Popescu C* **, Trandafir M*, Bădică AM*, Morar F*, Predeţeanu

More information

Short term in-patient rehabilitation in axial spondyloarthritis - the results of a 2-week program performed in daily clinical practice

Short term in-patient rehabilitation in axial spondyloarthritis - the results of a 2-week program performed in daily clinical practice Eppeland et al. BMC Research Notes 2013, 6:185 RESEARCH ARTICLE Short term in-patient rehabilitation in axial spondyloarthritis - the results of a 2-week program performed in daily clinical practice Siv

More information

Valuing Treatment With Infliximab for Ankylosing Spondylitis Using a Willingness-to-Pay Approach

Valuing Treatment With Infliximab for Ankylosing Spondylitis Using a Willingness-to-Pay Approach Arthritis Care & Research Vol. 70, No. 4, April 2018, pp 608 616 DOI 10.1002/acr.23299 2017, The Authors. Arthritis Care & Research published by Wiley Periodicals, Inc. on behalf of American College of

More information

The Relationship Between Clinical Activity And Function In Ankylosing Spondylitis Patients

The Relationship Between Clinical Activity And Function In Ankylosing Spondylitis Patients Bahrain Medical Bulletin, Vol.27, No. 3, September 2005 The Relationship Between Clinical Activity And Function In Ankylosing Spondylitis Patients Jane Kawar, MD* Hisham Al-Sayegh, MD* Objective: To assess

More information

What is Axial Spondyloarthritis?

What is Axial Spondyloarthritis? Physiotherapist Module 2 What is Axial Spondyloarthritis? How does it apply to physiotherapists? Claire Harris, Senior Physiotherapist, London North West Healthcare NHS Trust Susan Gurden, Advanced Physiotherapy

More information

Quality indicators, guidelines and outcome measures in ankylosing spondylitis

Quality indicators, guidelines and outcome measures in ankylosing spondylitis Quality indicators, guidelines and outcome measures in ankylosing spondylitis J. Zochling, J. Braun Jane Zochling, MBBS, MMed (ClinEpi), PhD, Research Fellow, Menzies Research Institute, Hobart, Australia;

More information

Amor B, Kahan A, Dougados M, et al. Sulfasalazine and ankylosing spondylitis. Ann Intern Med 1984;101:878.

Amor B, Kahan A, Dougados M, et al. Sulfasalazine and ankylosing spondylitis. Ann Intern Med 1984;101:878. Chapter 12 References Amor B, Kahan A, Dougados M, et al. Sulfasalazine and ankylosing spondylitis. Ann Intern Med 1984;101:878. Amor B, Dougados M, Listrat V, et al. Are classification criteria for spondylarthropathy

More information

Disease and psychological status in ankylosing spondylitis.

Disease and psychological status in ankylosing spondylitis. Article Disease and psychological status in ankylosing spondylitis. Martindale, J., Smith, J., Sutton, Chris J, Grennan, D., Goodacre, L. and Goodacre, J. A. Available at http://clok.uclan.ac.uk/132/ Martindale,

More information

Clinical and Imaging Efficacy of Infliximab in HLA B27 Positive Patients With Magnetic Resonance Imaging Determined Early Sacroiliitis

Clinical and Imaging Efficacy of Infliximab in HLA B27 Positive Patients With Magnetic Resonance Imaging Determined Early Sacroiliitis ARTHRITIS & RHEUMATISM Vol. 60, No. 4, April 2009, pp 946 954 DOI 10.1002/art.24408 2009, American College of Rheumatology Clinical and Imaging Efficacy of Infliximab in HLA B27 Positive Patients With

More information

The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial

The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial Handling editor Tore K Kvien 1 Department of Rheumatology, Rheumazentrum Ruhrgebiet, Herne, Germany 2 Department of Radiology, Charité Medical School, Berlin, Germany 3 Division of Arthritis & Rheumatic

More information

van der Heijde et al. Arthritis Research & Therapy (2018) 20:61 https://doi.org/ /s

van der Heijde et al. Arthritis Research & Therapy (2018) 20:61 https://doi.org/ /s van der Heijde et al. Arthritis Research & Therapy (2018) 20:61 https://doi.org/10.1186/s13075-018-1556-5 RESEARCH ARTICLE Clinical and MRI remission in patients with nonradiographic axial spondyloarthritis

More information

The Journal of Rheumatology Volume 38, no. 8

The Journal of Rheumatology Volume 38, no. 8 The Journal of Rheumatology Volume 38, no. 8 Serum MMP-3 Level as a Biomarker for Monitoring and Predicting Response to Etanercept Treatment in Ankylosing Spondylitis SUZANNE ARENDS, EVELINE van der VEER,

More information

Progression of Nonradiographic Axial Spondyloarthritis to Ankylosing Spondylitis

Progression of Nonradiographic Axial Spondyloarthritis to Ankylosing Spondylitis ARTHRITIS & RHEUMATOLOGY Vol. 68, No. 6, June 2016, pp 1415 1421 DOI 10.1002/art.39542 VC 2016, American College of Rheumatology Progression of Nonradiographic Axial Spondyloarthritis to Ankylosing Spondylitis

More information

THE BATH ANKYLOSING SPONDYLITIS PATIENT GLOBAL SCORE (BAS-G)

THE BATH ANKYLOSING SPONDYLITIS PATIENT GLOBAL SCORE (BAS-G) British Journal of Rheumatology 1996;35:66-71 THE BATH ANKYLOSING SPONDYLITIS PATIENT GLOBAL SCORE (BAS-G) S. D. JONES, A. STEINER,* S. L. GARRETT and A. CALIN Royal National Hospital for Rheumatic Diseases,

More information

Axial Spondyloarthritis: Issues & Controversies

Axial Spondyloarthritis: Issues & Controversies Axial Spondyloarthritis: Issues & Controversies Atul Deodhar, MD Professor of Medicine Oregon Health & Science University Portland, OR WRA 2018 Annual Meeting, Leavenworth, WA. 16 th September, 2018 Disclosures:

More information

A nkylosing spondylitis (AS) is a common chronic

A nkylosing spondylitis (AS) is a common chronic 1046 EXTENDED REPORT Analysing chronic spinal changes in ankylosing spondylitis: a systematic comparison of conventional x rays with magnetic resonance imaging using established and new scoring systems

More information

T he emergence of new treatment options in ankylosing

T he emergence of new treatment options in ankylosing iii24 EXTENDED REPORT Treatment trials in ankylosing spondylitis: current and future considerations D van der Heijde, J Braun, D McGonagle, J Siegel... See end of article for authors affiliations... Correspondence

More information

Optimisation of rheumatology assessments the actual situation in axial spondyloarthritis including ankylosing spondylitis

Optimisation of rheumatology assessments the actual situation in axial spondyloarthritis including ankylosing spondylitis Optimisation of rheumatology assessments the actual situation in axial spondyloarthritis including ankylosing spondylitis J. Braun, U. Kiltz, X. Baraliakos, D. van der Heijde Rheumazentrum Ruhrgebiet,

More information

Anja Weiß 1*, In-Ho Song 2, Hildrun Haibel 2, Joachim Listing 1 and Joachim Sieper 1,2

Anja Weiß 1*, In-Ho Song 2, Hildrun Haibel 2, Joachim Listing 1 and Joachim Sieper 1,2 Weiß et al. Arthritis Research & Therapy 2014, 16:R35 RESEARCH ARTICLE Open Access Good correlation between changes in objective and subjective signs of inflammation in patients with short- but not long

More information

Certolizumab pegol (Cimzia) for the treatment of ankylosing spondylitis second or third line

Certolizumab pegol (Cimzia) for the treatment of ankylosing spondylitis second or third line Certolizumab pegol (Cimzia) for the treatment of ankylosing spondylitis second or third line August 2011 This technology summary is based on information available at the time of research and a limited

More information

2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis. Online supplementary material

2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis. Online supplementary material 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis Online supplementary material 1. Introduction A systematic literature review (SLR) was performed to inform the

More information

Eligibility criteria for TNFi therapy in axspa: BASDAI vs ASDAS

Eligibility criteria for TNFi therapy in axspa: BASDAI vs ASDAS Eligibility criteria for TNFi therapy in axspa: BASDAI vs ASDAS Abstract Background The Ankylosing Spondylitis Disease Activity Score (ASDAS) has been developed as a composite disease activity measure

More information

T he spondyloarthritides (SpA) comprise five subtypes:

T he spondyloarthritides (SpA) comprise five subtypes: 1305 EXTENDED REPORT Magnetic resonance imaging of the spine and the sacroiliac joints in ankylosing spondylitis and undifferentiated spondyloarthritis during treatment with etanercept M Rudwaleit*, X

More information

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Health Technology Appraisal

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Health Technology Appraisal NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Proposed Health Technology Appraisal Secukinumab for treating ankylosing spondylitis after inadequate response to non-steroidal anti-inflammatory drugs

More information

2004 Health Press Ltd.

2004 Health Press Ltd. ... Ankylosing spondylitis Maxime Dougados MD Professor of Rheumatology Hôpital Cochin René Descartes University Paris, France Désirée van der Heijde MD PhD Professor of Rheumatology University Hospital

More information

Vitamin D status in spondyloarthritis: results of the ASAS-COMOSPA international study

Vitamin D status in spondyloarthritis: results of the ASAS-COMOSPA international study Vitamin D status in spondyloarthritis: results of the ASAS-COMOSPA international study S. Fernandes 1,2, A. Etcheto 1,3, D. van der Heijde 4, R. Landewé 5, F. van den Bosch 6, M. Dougados 1,3, A. Moltó

More information

Quantitative assessment of patients with rheumatic diseases

Quantitative assessment of patients with rheumatic diseases ORIGINAL ARTICLE Routine Assessment of Patient Index Data (RAPID3) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Scores Yield Similar Information in 85 Korean Patients With Ankylosing

More information

Chapter 2 Criteria and Disease Activity Measures in Axial Spondyloarthropathies

Chapter 2 Criteria and Disease Activity Measures in Axial Spondyloarthropathies Chapter 2 Criteria and Disease Activity Measures in Axial Spondyloarthropathies Jose Aliling 1 and Lawrence H Brent 1* Einstein Medical Center, USA * Corresponding Author: Lawrence H Brent, Einstein Medical

More information

adalimumab, 40mg/0.8mL, solution for injection (Humira ) SMC No. (858/13) AbbVie Ltd (previously part of Abbott)

adalimumab, 40mg/0.8mL, solution for injection (Humira ) SMC No. (858/13) AbbVie Ltd (previously part of Abbott) adalimumab, 40mg/0.8mL, solution for injection (Humira ) SMC No. (858/13) AbbVie Ltd (previously part of Abbott) 08 March 2013 The Scottish Medicines Consortium (SMC) has completed its assessment of the

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) European Medicines Agency Pre-Authorisation Evaluation of Medicines for Human Use London, 23 April 2009 Doc. Ref. CPMP/EWP/4891/03 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON CLINICAL

More information

Department of Radiology, Aarhus University Hospital, Aarhus, Denmark; 4. Key words MRI, sacroiliitis, ankylosing spondylitis, axial spondyloarthritis.

Department of Radiology, Aarhus University Hospital, Aarhus, Denmark; 4. Key words MRI, sacroiliitis, ankylosing spondylitis, axial spondyloarthritis. Gadolinium contrast-enhanced MRI sequence does not have an incremental value in the assessment of sacroiliitis in patients with early inflammatory back pain by using MRI in combination with pelvic radiographs:

More information

Radiographic sacroiliitis develops predictably over time in a cohort of familial spondyloarthritis followed longitudinally

Radiographic sacroiliitis develops predictably over time in a cohort of familial spondyloarthritis followed longitudinally RHEUMATOLOGY Rheumatology 2017;56:811 817 doi:10.1093/rheumatology/kew496 Advance Access publication 4 February 2017 Original article Radiographic sacroiliitis develops predictably over time in a cohort

More information

Frequency of low bone mineral density in spondyloarthropathy presenting at a tertiary care hospital

Frequency of low bone mineral density in spondyloarthropathy presenting at a tertiary care hospital 973 ORIGINAL ARTICLE Frequency of low bone mineral density in spondyloarthropathy presenting at a tertiary care hospital Lubna Nazir, Shafique Rehman, Amir Riaz, Mohammad Saeed, Tahira Perveen Abstract

More information

Current Concept of Spondyloarthritis: Special Emphasis on Early Referral and Diagnosis

Current Concept of Spondyloarthritis: Special Emphasis on Early Referral and Diagnosis DOI 10.1007/s11926-012-0274-2 SERONEGATIVE ARTHRITIS (MA KHAN, SECTION EDITOR) Current Concept of Spondyloarthritis: Special Emphasis on Early Referral and Diagnosis Salih Ozgocmen & Muhammad Asim Khan

More information

Chapter 2. Overview of ankylosing spondylitis

Chapter 2. Overview of ankylosing spondylitis Chapter 2 Overview of ankylosing spondylitis The concept and classification of spondyloarthritis The term spondyloarthritis (SpA) comprises AS, reactive arthritis, arthritis/spondylitis associated with

More information

ISPUB.COM. Effects Of Physical And Rehabilitative Treatment On Quality Of Life Of Ankylosing Spondylitis Patients

ISPUB.COM. Effects Of Physical And Rehabilitative Treatment On Quality Of Life Of Ankylosing Spondylitis Patients ISPUB.COM The Internet Journal of Orthopedic Surgery Volume 21 Number 2 Effects Of Physical And Rehabilitative Treatment On Quality Of Life Of Ankylosing Spondylitis Patients B Singh, A Upadhyay, M Garg,

More information

Factors related to health-related quality of life in ankylosing spondylitis, overall and stratified by sex

Factors related to health-related quality of life in ankylosing spondylitis, overall and stratified by sex Law et al. Arthritis Research & Therapy (2018) 20:284 https://doi.org/10.1186/s13075-018-1784-8 RESEARCH Factors related to health-related quality of life in ankylosing spondylitis, overall and stratified

More information

Nonradiographic axial spondyloarthritis: clinical and therapeutic relevance

Nonradiographic axial spondyloarthritis: clinical and therapeutic relevance Ghosh and Ruderman Arthritis Research & Therapy (2017) 19:286 DOI 10.1186/s13075-017-1493-8 REVIEW Nonradiographic axial spondyloarthritis: clinical and therapeutic relevance Nilasha Ghosh and Eric M.

More information

Low bone mineral density predicts the formation of new syndesmophytes in patients with axial spondyloarthritis

Low bone mineral density predicts the formation of new syndesmophytes in patients with axial spondyloarthritis Kim et al. Arthritis Research & Therapy (2018) 20:231 https://doi.org/10.1186/s13075-018-1731-8 RESEARCH ARTICLE Open Access Low bone mineral density predicts the formation of new syndesmophytes in patients

More information

Cosentyx clinical trial program in spondyloarthritis (SpA) 1-5

Cosentyx clinical trial program in spondyloarthritis (SpA) 1-5 Cosentyx clinical trial program in spondyloarthritis (SpA) 1-5 There are four pivotal trials; two in psoriatic arthritis, two in ankylosing spondylitis More than 10,000 patients have been treated with

More information

ORIGINAL ARTICLE. Ho Yin Chung & Chak Sing Lau & Ka Pik Wu & Woon Sing Wong & Mo Yin MOK

ORIGINAL ARTICLE. Ho Yin Chung & Chak Sing Lau & Ka Pik Wu & Woon Sing Wong & Mo Yin MOK Clin Rheumatol (2011) 30:947 953 DOI 10.1007/s10067-011-1693-6 ORIGINAL ARTICLE Comparison of performance of the Assessment of Spondyloarthritis International Society, the European Spondyloarthropathy

More information

Guideline on the Clinical Investigation of Medicinal Products for the Treatment of Axial Spondyloarthritis

Guideline on the Clinical Investigation of Medicinal Products for the Treatment of Axial Spondyloarthritis 12 October 2017 EMA/CPMP/EWP/4891/03 Rev.1 Committee for Medicinal Products for Human Use (CHMP) Guideline on the Clinical Investigation of Medicinal Products for the Treatment of Axial Draft agreed by

More information

Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial

Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial 1 Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands; 2 University of Denver, Denver, Colorado, USA; 3 Medical Department I, Rheumatology, Benjamin Franklin Hospital,

More information

Introduction. Natural Progression of AS. Sacroiliac Joint. Clinical Features and Assessment of Ankylosing Spondylitis

Introduction. Natural Progression of AS. Sacroiliac Joint. Clinical Features and Assessment of Ankylosing Spondylitis Clinical Features and Assessment of Ankylosing Spondylitis Dr. YIM, Cheuk Wan Specialist in Rheumatology United Christian Hospital Introduction Ankylo=fusion Spondylitis=inflammation of spine Affect 0.1-0.5%

More information

Impact of obesity on the response to tumor necrosis factor inhibitors in axial spondyloarthritis

Impact of obesity on the response to tumor necrosis factor inhibitors in axial spondyloarthritis Micheroli et al. Arthritis Research & Therapy (2017) 19:164 DOI 10.1186/s13075-017-1372-3 RESEARCH ARTICLE Impact of obesity on the response to tumor necrosis factor inhibitors in axial spondyloarthritis

More information

AWMSG SECRETARIAT ASSESSMENT REPORT. Certolizumab pegol (Cimzia ) 200 mg solution for injection. Reference number: 1211 FULL SUBMISSION

AWMSG SECRETARIAT ASSESSMENT REPORT. Certolizumab pegol (Cimzia ) 200 mg solution for injection. Reference number: 1211 FULL SUBMISSION AWMSG SECRETARIAT ASSESSMENT REPORT Certolizumab pegol (Cimzia ) 200 mg solution for injection Reference number: 1211 FULL SUBMISSION This report has been prepared by the All Wales Therapeutics and Toxicology

More information

Golimumab, compared to placebo, significantly improved symptoms in adults with active nonradiographic

Golimumab, compared to placebo, significantly improved symptoms in adults with active nonradiographic golimumab 50mg/0.5mL solution for injection in pre-filled pen or syringe and 100mg/mL solution for injection in pre-filled pen (Simponi ) SMC No. (1124/16) Merck Sharp & Dohme Limited 8 January 2016 The

More information

Cover Page. The handle holds various files of this Leiden University dissertation.

Cover Page. The handle   holds various files of this Leiden University dissertation. Cover Page The handle http://hdl.handle.net/1887/29572 holds various files of this Leiden University dissertation. Author: Berg, Rosaline van den Title: Spondyloarthritis : recognition, imaging, treatment

More information

Jane T Osterhaus 1* and Oana Purcaru 2

Jane T Osterhaus 1* and Oana Purcaru 2 Osterhaus and Purcaru Arthritis Research & Therapy 2014, 16:R164 RESEARCH ARTICLE Open Access Discriminant validity, responsiveness and reliability of the arthritis-specific Work Productivity Survey assessing

More information

Cover Page. The handle holds various files of this Leiden University dissertation

Cover Page. The handle   holds various files of this Leiden University dissertation Cover Page The handle http://hdl.handle.net/1887/43590 holds various files of this Leiden University dissertation Author: Machado, Pedro Title: Health and imaging outcomes in axial spondyloarthritis Issue

More information

Gender differences in effectiveness of treatment in rheumatic diseases

Gender differences in effectiveness of treatment in rheumatic diseases Gender differences in effectiveness of treatment in rheumatic diseases Irene van der Horst-Bruinsma Associate Professor Rheumatology Center of Excellence of Axial Spondyloarthritis ARC/VU University Medical

More information

Assessment of Pulmonary Function Test (Pft) In Patients of Ankylosing Spondylitis

Assessment of Pulmonary Function Test (Pft) In Patients of Ankylosing Spondylitis IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 16, Issue 8 Ver. X (Aug. 2017), PP 63-68 www.iosrjournals.org Assessment of Pulmonary Function Test (Pft)

More information

Mikhail Protopopov 1, Joachim Sieper 1, Hildrun Haibel 1, Joachim Listing 2, Martin Rudwaleit 1,3 and Denis Poddubnyy 1,2*

Mikhail Protopopov 1, Joachim Sieper 1, Hildrun Haibel 1, Joachim Listing 2, Martin Rudwaleit 1,3 and Denis Poddubnyy 1,2* Protopopov et al. Arthritis Research & Therapy (2017) 19:240 DOI 10.1186/s13075-017-1453-3 RESEARCH ARTICLE Open Access Relevance of structural damage in the sacroiliac joints for the functional status

More information

Sustained efficacy and safety, including patient-reported outcomes, with etanercept treatment over 5 years in patients with ankylosing spondylitis

Sustained efficacy and safety, including patient-reported outcomes, with etanercept treatment over 5 years in patients with ankylosing spondylitis Sustained efficacy and safety, including patient-reported outcomes, with etanercept treatment over 5 years in patients with ankylosing spondylitis E. Martín-Mola 1, J. Sieper 2, M. Leirisalo-Repo 3, B.A.C.

More information

Cosentyx clinical trial program in spondyloarthritis (SpA) 1-7

Cosentyx clinical trial program in spondyloarthritis (SpA) 1-7 Cosentyx clinical trial program in spondyloarthritis (SpA) 1-7 There are five pivotal trials; three in psoriatic arthritis, two in ankylosing spondylitis More than 10,000 patients have been treated with

More information

Clinical and spinal radiographic outcome in axial spondyloarthritis Maas, Fiona

Clinical and spinal radiographic outcome in axial spondyloarthritis Maas, Fiona University of Groningen Clinical and spinal radiographic outcome in axial spondyloarthritis Maas, Fiona IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish

More information

A simplified version of Ankylosing Spondylitis Disease Activity Score (ASDAS) in patients with ankylosing spondylitis

A simplified version of Ankylosing Spondylitis Disease Activity Score (ASDAS) in patients with ankylosing spondylitis DOI 10.1007/s10067-012-2056-7 ORIGINAL ARTICLE A simplified version of Ankylosing Spondylitis Disease Activity Score (ASDAS) in patients with ankylosing spondylitis Fernando A. Sommerfleck & Emilce E.

More information

Ankylosing spondylitis (AS) is a chronic inflammatory disorder

Ankylosing spondylitis (AS) is a chronic inflammatory disorder DOI 10. 5001/omj.2012.109 Original Article Health-related Quality of Life Assessment on 100 Tunisian Patients with Ankylosing Spondylitis using the SF-36 Survey Wafa Hamdi, Dhouha Azzouz, Mohamed Mehdi

More information

Ankylosing spondylitis (Bechterew's Disease) [Name of Writer] [Name of Institute]

Ankylosing spondylitis (Bechterew's Disease) [Name of Writer] [Name of Institute] Ankylosing spondylitis 1 Running Head: ANKYLOSING SPONDYLITIS Ankylosing spondylitis (Bechterew's Disease) [Name of Writer] [Name of Institute] Ankylosing spondylitis 2 Ankylosing spondylitis (Bechterew's

More information

Serum sclerostin as a possible biomarker in ankylosing spondylitis: a casecontrol

Serum sclerostin as a possible biomarker in ankylosing spondylitis: a casecontrol Serum sclerostin as a possible biomarker in ankylosing spondylitis: a casecontrol study Fabio Massimo Perrotta 1, MD, Fulvia Ceccarelli 2, MD, PhD, Cristiana Barbati 2, PhD, Tania Colasanti 2, PhD, Antonia

More information

Characterization of Patients With Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis in the US-Based Corrona Registry

Characterization of Patients With Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis in the US-Based Corrona Registry Arthritis Care & Research Vol. 70, No. 11, November 2018, pp 1661 1670 DOI 10.1002/acr.23534 2018, The Authors. Arthritis Care & Research published by Wiley Periodicals, Inc. on behalf of American College

More information

Magnetic Resonance Imaging of Inflammatory Lesions in the Spine in Ankylosing Spondylitis Clinical Trials: Is Paramagnetic Contrast Medium Necessary?

Magnetic Resonance Imaging of Inflammatory Lesions in the Spine in Ankylosing Spondylitis Clinical Trials: Is Paramagnetic Contrast Medium Necessary? Magnetic Resonance Imaging of Inflammatory Lesions in the Spine in Ankylosing Spondylitis Clinical Trials: Is Paramagnetic Contrast Medium Necessary? KAY-GEERT A. HERMANN, ROBERT B.M. LANDEWÉ, JÜRGEN BRAUN,

More information

Imaging of axial spondyloarthritis including ankylosing spondylitis

Imaging of axial spondyloarthritis including ankylosing spondylitis Imaging of axial spondyloarthritis including ankylosing spondylitis ACR 2012 Prof. Dr. med. J. Braun Rheumazentrum Ruhrgebiet, Herne Ruhr-Universität Bochum Germany Modified New York Criteria 1984 for

More information

Heel pain in spondyloarthritis: results of a cross-sectional study of 275 patients

Heel pain in spondyloarthritis: results of a cross-sectional study of 275 patients Heel pain in spondyloarthritis: results of a cross-sectional study of 275 patients E. Koumakis, L. Gossec, M. Elhai, V. Burki, A. Durnez, I. Fabreguet, M. Meyer, J. Payet, F. Roure, S. Paternotte, M. Dougados

More information

Clinical and MRI responses to etanercept in early non-radiographic axial spondyloarthritis: 48-week results from the EMBARK study

Clinical and MRI responses to etanercept in early non-radiographic axial spondyloarthritis: 48-week results from the EMBARK study EXTENDED REPORT Clinical and MRI responses to etanercept in early non-radiographic axial spondyloarthritis: 48-week results from the EMBARK study Walter P Maksymowych, 1 Maxime Dougados, 2 Désirée van

More information

Overview of axial spondyloarthritis

Overview of axial spondyloarthritis Chapter 2 Overview of axial spondyloarthritis The concept and classification of spondyloarthritis The term spondyloarthritis (SpA) comprises ankylosing spondylitis (AS), reactive arthritis, arthritis/spondylitis

More information

X. Baraliakos 1, A.J. Kivitz 2, A.A. Deodhar 3, J. Braun 1, J.C. Wei 4, E.M. Delicha 5, Z. Talloczy 6, B. Porter 6, for the MEASURE 1 study group

X. Baraliakos 1, A.J. Kivitz 2, A.A. Deodhar 3, J. Braun 1, J.C. Wei 4, E.M. Delicha 5, Z. Talloczy 6, B. Porter 6, for the MEASURE 1 study group Long-term effects of interleukin-17a inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the Phase 3 MEASURE 1 trial X. Baraliakos 1, A.J.

More information

Abstract. Arends et al. Arthritis Research & Therapy 2011, 13:R94

Abstract. Arends et al. Arthritis Research & Therapy 2011, 13:R94 RESEARCH ARTICLE Open Access Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort

More information

Netherlands, Atrium Medical Center, Heerlen, the Netherlands. Rheumatology Unit, Department of Medicine DIMED, University of Padova, Italy

Netherlands, Atrium Medical Center, Heerlen, the Netherlands. Rheumatology Unit, Department of Medicine DIMED, University of Padova, Italy DR. SOFIA RAMIRO (Orcid ID : 0000-0002-8899-9087) Article type : Full Length Is it useful to repeat MRI of the sacroiliac joints after three months or one year in the diagnostic process of patients with

More information

Keywords: ankylosing spondylitis, translation, questionnaires, BASFI, health status.

Keywords: ankylosing spondylitis, translation, questionnaires, BASFI, health status. ORIGINAL ARTICLE Cross-cultural adaptation and validation of the Brazilian-Portuguese version of the Bath Ankylosing Spondylitis Functional Index (BASFI) Karla Garcez Cusmanich 1, Sérgio Candido Kowalski

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium etanercept 25mg vial of powder for subcutaneous injection (Enbrel ) (No. 212/05) Wyeth New indication: severe active ankylosing spondylitis inadequately controlled by conventional

More information

Nonsurgical management of ankylosing spondylitis

Nonsurgical management of ankylosing spondylitis Neurosurg Focus 24 (1):E5, 2008 JAYPAL REDDY SANGALA, M.D., M.CH., D.N.B., ELIAS DAKWAR, M.D., JUAN URIBE, M.D., AND FERNANDO VALE, M.D. Department of Neurological Surgery, University of South Florida,

More information

Spondyloarthritis Physical Exam Measures. Axial SpA Measures. Ear Anatomy (Wikipedia) 5/4/2018. Tragus to Wall and Occiput to Wall Measurement

Spondyloarthritis Physical Exam Measures. Axial SpA Measures. Ear Anatomy (Wikipedia) 5/4/2018. Tragus to Wall and Occiput to Wall Measurement AxSpA Measures in Clinical Trials Spondyloarthritis Physical Exam Measures Philip Mease MD, MACR Director, Rheumatology Research, Swedish-Providence-St. Joseph Health Systems Clinical Professor, University

More information

ABSTRACT ORIGINAL RESEARCH. Laure Tant. Nadine Delmotte. Maria Van den Enden. Valerie Gangji. Herman Mielants

ABSTRACT ORIGINAL RESEARCH. Laure Tant. Nadine Delmotte. Maria Van den Enden. Valerie Gangji. Herman Mielants Rheumatol Ther (2017) 4:121 132 DOI 10.1007/s40744-016-0051-1 ORIGINAL RESEARCH High Prevalence of Undiagnosed Axial Spondyloarthritis in Patients with Chronic Low Back Pain Consulting Non-Rheumatologist

More information

The effectiveness of intensive group exercise on patients with ankylosing spondylitis

The effectiveness of intensive group exercise on patients with ankylosing spondylitis Clinical Rehabilitation 2003; 17: 631 636 The effectiveness of intensive group exercise on patients with ankylosing spondylitis Yildiz Analay Istanbul University, Cerrahpasa Faculty of Medicine, Department

More information

ABSTRACT Objective: To validate and refine two sets of candidate criteria for the classification/diagnosis of axial spondyloarthritis

ABSTRACT Objective: To validate and refine two sets of candidate criteria for the classification/diagnosis of axial spondyloarthritis 1 Rheumatology, Med Klinik I, Charité, Campus Benjamin Franklin, Berlin, Germany; 2 Leiden University Medical Center, Leiden, The Netherlands; 3 Maastricht University Medical Center, Maastricht, The Netherlands;

More information

First signs and symptoms of spondyloarthritis data from an inception cohort with a disease course of two years or less (REGISPONSER- Early)

First signs and symptoms of spondyloarthritis data from an inception cohort with a disease course of two years or less (REGISPONSER- Early) Rheumatology 9;48:4 9 Advance Access publication 1 February 9 doi:1.193/rheumatology/ken6 First signs and symptoms of spondyloarthritis data from an inception cohort with a disease course of two years

More information